EphrinA1 binding with receptor EphA2 suppresses malignant mesothelioma (MM) growth. The mechanisms whereby EphrinA1 attenuates the MM cell (MMC) growth are not clear. In this study, we report that the activation of MMCs with EphrinA1 leads to an induction of let-7 microRNA (miRNA) expression, repression of RAS proto-oncogene and the attenuation of MM tumor growth. The expression of miRNAs was determined by reverse transcription-quantitative polymerase chain reaction and in situ hybridization. RAS expression was determined by q-PCR, western blotting and immunofluorescence. MMC proliferation and tumor growth were determined by WST-1 and Matrigel assay, respectively. EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs. In contrast, EphrinA1 activation significantly downregulated H-RAS, K-RAS and N-RAS expression and inhibited MMC proliferation and tumor growth. In MMCs transfected with 2 0 -O-methyl antisense oligonucleotides to let-7 miRNA, EphrinA1 activation failed to inhibit the proliferative response and tumor growth. In mismatch antisense oligonucleotidetreated MMCs, the proliferation and tumor growth were comparable to untreated proliferating cells. Furthermore, the transfection of MMCs with let-7a miRNA precursor inhibited RAS expression and attenuated MMC tumor growth. Our data revealed that EphrinA1 signaling induces let-7 miRNA expression and attenuates MM tumor growth by targeting RAS proto-oncogene in MMCs.
Introduction
Malignant mesothelioma (MM) is an aggressive pleural tumor resistant to conventional therapies. The prognosis of patients with advanced and metastatic MM is poor. [1] [2] [3] Approximately 3000 new cases are reported each year in the United States, and more than 10 000 are reported worldwide. 2, 4 As mesothelioma symptoms do not arise until late stages, the majority of mesothelioma patients are diagnosed in an advanced stage of malignancy. 5 MM is resistant to all currently available treatments; therefore, understanding the mechanisms involved in the growth of MM may provide insights for the development of new therapeutic strategies to treat patients with MM. Recently, Eph receptors, Ephrin expression patterns and their functional outcomes have been linked to various physiological and pathological processes, particularly tumorogenesis.
Ephrins have been first identified as membrane-bound ligands for Eph receptor tyrosine kinases. Ephrins were recognized as important modulators in the development of the nervous system and organization of vasculature. [6] [7] [8] EphrinA1 expression levels were low in tumors where the EphA2 was overexpressed. 9 EphrinA1-mediated signals were tumor suppressive. In addition, the ectopic expression of EphrinA1 in glioblastoma and other tumors resulted in significant defects in the migration and proliferation of malignant cells. 10, 11 In mammary carcinoma, EphrinA1 activation of EphA2 attenuated the activity of RAS oncogene, suggesting a negative feedback loop that regulates the activity of RAS. 7 We have reported that activation of receptor EphA2 by its ligand EphrinA1 induces marked reduction in the anchorage-independent growth of MM tumor. Furthermore, vector-based overexpression of EphrinA1 in MM cells (MMCs) demonstrated similar results and also confirmed the tumor-suppressive properties. 12 However, the mechanisms by which EphrinA1 suppresses the tumor growth in MM are not known.
Increasing evidence suggests a potential link between EphA2 over-expression and signaling by RAS oncogenes. High levels of EphA2 have been observed in RAStransformed cells in mammary tumors of transgenic mice that express mutant RAS. 13 RAS is a member of the small GTPase superfamily and the signaling mediator of Eph receptors predominantly associated with cellular proliferation, adhesion and migration. 14 In MM, RAS expression was found to be higher and the effectors for RAS, which promotes cellular proliferation, were found to be activated. 15 Furthermore, in melanoma silencing the expression of RAS gene inhibited the migration and invasion. This inhibition was also accompanied by downregulation of EphA2, indicating that RAS signaling regulates receptor EphA2 expression. 16 MicroRNA (miRNAs) are a recently discovered class of small non-coding o22-nucleotide RNAs and recognized as one of the major regulatory gene families. They are known to play an important role in numerous developmental processes via repressing gene expression at the post-transcriptional level by directly cleaving targeted messenger RNA (mRNA) or by translational repressing. 17, 18 MiRNAs regulate gene expression through incomplete base pairing to a complementary sequence in the 3 0 -untranslated region of a target mRNA. 18, 19 Let-7 miRNA functions as a tumor suppressor by silencing RAS and high-mobility group AThook2. 20 Let-7 was first identified in Caenorhabditis elegans as a regulator of developmental timing and proliferation of cells. 21 Let-7 contains multiple putative complementary sites in the 3 0 -untranslated region of all three RAS genes (H-RAS, K-RAS and N-RAS) in humans, and it negatively regulates RAS protein levels. RAS translation is known to be regulated by let-7 miRNA in lung cancer. 22 Because Ephrin-Eph system has been linked with important biological outcomes, there has also been a recent emphasis on understanding how miRNA mediates these events and regulates cellular proliferation and tumor growth. Therefore, we reasoned if EphEphrin-mediated signaling modulate miRNA expression that may play a potential role in MM growth.
In this report, we investigated the mechanisms of EphrinA1-mediated tumor growth inhibition in MM. We have identified a novel mechanism that EphrinA1 treatment leads to let-7 miRNA expression in MM. The EphrinA1 treatment also resulted in the downregulation of RAS oncogene and significant reduction in MMC proliferation and tumor growth. In addition, when MMCs were transfected with 2 0 -O-methyl antisense oligonucleotide (2 0 -OMO) designed to inhibit the activity of let-7 and treated with EphrinA1, the RAS expression was restored and failed to inhibit the tumor growth. Furthermore, when MMCs were transfected with let-7a pre-miRNA, the RAS oncogene expression, cell proliferation and tumor growth was decreased and was comparable with EphrinA1-treated cultures. These findings suggest that EphrinA1 may be a promising candidate in the development of novel therapeutic strategies against MM.
Materials and methods

MMC culture
Two mesothelioma cell lines, CRL-2081 (biphasic, fibroblast morphology) and CRL-5830 (epitheliod, epithelial morphology), were obtained from the American Type Culture Collection (Manassas, VA). They were grown in RPMI-1640 culture media containing 10% fetal bovine serum (Atlanta Biologicals s , Lawrenceville, GA), penicillin (100 U ml
À1
) and streptomycin (100 mg ml À1 ) purchased from Sigma-Aldrich (St Louis, MO). The cells were plated in 75 cm 2 tissue culture flasks (Corning Costar, MA) and incubated at 37 1C in 5% CO 2 and 95% air. The monolayer was confluent between 2 and 3 days. MMCs were counted and subcultured in 60-mm cell culture dishes (5 Â 10 5 cells per dish) as reported earlier. 23 
Treatment of MMCs
Briefly, MMC cultures were activated with or without 3 mg ml À1 of recombinant Ephrin-A1/Fc chimera (R&D Systems, Minneapolis, MN) in serum-free RPMI-1640 for the indicated times. 12 The cells were transfected with a let7a 2 0 -OMO at a concentration of 50 and 100 nM, which blocks endogenous let-7 miRNA or mismatch oligonucleotide (mis-MO) synthesized from Sigma (St Louis, MO) by using Lipofectamine 2000, and few wells were left untreated. MMCs were also transfected with let-7a miRNA precursor or scrambled-miRNA (Ambion, Austin, TX) and then processed for various assays.
Quantitative real-time PCR Total RNA was extracted from CRL-2081 and CRL-5830 cells with TRIzol reagent (Invitrogen, Frederick, MD) and first-strand complementary DNA was generated using Enhanced Avain Reverse Transcriptase (Sigma Aldrich). The primers used were synthesized from Sigma Aldrich. The SYBR Green JumpStart Taq Ready Mixt was used to perform polymerase chain reaction (PCR) as reported earlier, 24, 25 and the primer sequences were listed in Table 1 24, 25 Gene name Primer sequence (5
Abbreviations: F, forward; PCR, polymerase chain reaction; R, reverse; RT, reverse transcription. 27 Typically, 30 mg of total protein was resolved on 4-20% Tris glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (Bio-Rad, Hercules, CA). Proteins were transferred to polyvinylidene fluoride membranes. The blots were blocked and incubated with either mouse pan-RAS or anti-rabbit EphA2 antibodies (Cell Signaling, Danvers, MA) at a dilution of 1:200 overnight at 4 1C.The immunocomplex was washed three times, and then incubated with either goat-anti-mouse or goat-anti-rabbit immunoglobulin G secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:2000 dilution for 1 h at room temperature. RAS and EphA2 proteins were detected by enhanced Immuno-Start HRP Chemiluminescent Kit (Bio-Rad).
MMC proliferation MMC proliferation was measured by a colorimetric assay kit (WST-1; Roche Diagnostics, Indianapolis, IN), as reported earlier. 23 In brief, MMCs were plated in 96-well microplate, at a density of 1 Â 10 4 cells per well. Transfected and control cells without any treatment were used for activation with or without 3 mg ml À1 EphrinA1 in serum-free RPMI 1640 for 48 h. Proliferation was determined by incubating cells with WST-1 reagent for 4 h and the absorbance was measured at 450 nm wavelength. MMCs were harvested and proliferation was also measured by direct cell counting.
Immunofluorescence staining
MMCs were grown in 35 mm glass-bottomed dishes coated with collagen, at a density of 5 Â 10 4 cells per well and transfected with or without a 2 0 -OMO, which blocks endogenous let-7 or mis-MO by using Lipofectamine 2000 and dishes were incubated for 2 h at 37 1C as reported earlier. 24, 25 Transfected and cells treated with or without EphrinA1 in serum-free RPMI 1640 for 24 h. Cells were fixed with cold 4% paraformaldehyde and incubated with pan-RAS monoclonal antibody against RAS protein, and anti-rabbit EphA2 monoclonal (Cell Signaling Technology, Danvers, MA) at room temperature for 1 h, followed by Texas red with goat anti-mouse immunoglobulin G (Invitrogen, Carlsbad, CA), fluorescein isothiocyanate for EPhA2 and 4 0 ,6-diamidino-2-phenylindole was used for nuclear staining for 1 h, respectively. After removal of antibodies, cells were rinsed with phosphate-buffered saline and treated with anti-fade reagents (Slow fade Anti-fade Kit; Invitrogen), and fluorescence was immediately observed using Carl Zeiss AxioVison (Zeiss, Thornwood, NY) immunofluorescence microscope.
In situ hybridization MMCs were cultured in four-chambered slides and some cultures were activated either with EphrinA1 or transfected with pre-miR let-7a precursor sequence. The cell cultures were processed for in situ hybridization according to de Planell-Saguer et al. 28 In brief, slides were fixed in 4% paraformaldehyde and permeabilized with pepsin (0.1% in 10 mM HCl). After dehydration, pre-hybridization was performed for 30 min at 55 1C in pre-hybridization buffer. The slides were hybridized with 25 nM of digoxigenin-labeled locked nucleic acid probes for let-7a miRNA or scrambled-miRNA (sc probe) using miRCURYt locked nucleic acid probes obtained from Exiqon (Woburn, MA). The probe sequences used were as follows: has-let-7a, /5DigN/AACTATACAACCTACT ACCTCA/3Dig_N; scrambled-miRNA, /5DigN/GTG TAACACGTCTATACGCCCA/3Dig_N. Denaturation of the probes was performed at 80 1C for 2 min. The slides were incubated overnight at 37 1C in a humidified chamber. After washing the slides in wash buffer (Roche, Bedford, MA), they were treated with blocking solution for 3 h at room temperature. The slides were incubated at room temperature for 1 h with alkaline phosphataseconjugated anti-digoxigenin fragment (1:1500; Roche Diagnostics,) and again washed twice in phosphatebuffered saline containing Tween-20. The slides were incubated with NBT (nitro-blue tetrazolium chloride)/ BCIP (5-bromo-4-chloro-3 0 -indolyphosphate p-toluidine salt) substrate for 10 min in the dark, washed in distilled water, and then counter-stained with nuclear fast red (Fishers Scientific, Pittsburgh, PA). The cells were viewed under bright field at Â 200 magnification by using Nikon Microscope (TE200-S; Nikon Metrology, Brighton, MI).
Tumor formation and tumor growth analysis MMCs (5 Â 10 3 ) were cultured in 24-well culture plate coated with 200 ml of Matrigel (BD Biosciences, Bedford, MA) per well, followed by polymerization for 30 min at 37 1C as reported earlier. 12 Transfected and control cells were treated with or without 3 mg ml
À1
EphrinA1 in serum-free RPMI 1640 for 24 h. Media were changed every 3 days and the number of tumor colonies formed was photographed at Â 100 magnification.
Statistical analysis
The Sigma Stat 3.5 statistical software program was used to calculate statistical significance. Analysis of variance was used to compare the experimental groups from the control groups. The differences at Po0.05 were considered statistically significant.
Results
EphrinA1 activation upregulates let-7 expression in MMCs
To evaluate the activation of EphA2 receptors with EphrinA1 resulted in increasing levels of let-7 miRNA expression in activated MMCs, quantitative PCR (qPCR) and in situ hybridization were performed. Real-time qPCR analysis showed that let-7 isoforms (let-7a1, let-7 a3, let-7f1 and let-7f2) are expressed relatively high (log 13.01, 3.70, 4.03 and 4.05, respectively) in EphrinA1-activated MMC1 (Figures 1a-d) . In MMC2, EphrinA1 activation enhanced these miRNA expressions. The let7a1 miRNA expression was significantly high when compared with other let-7 miRNAs, in both cell lines. EphrinA1 at a lower concentration was ineffective; however, a higher concentration (42 mg) showed significant effects when compared with unstimulated MMCs. 12 In addition, the in situ hybridization with miRCURYt locked nucleic acid probe further confirmed the upregulation of let-7a miRNA in EphrinA1-activated MMCs when compared with untreated control MMCs (Figure 1e ). Let-7a precursor-transfected MMCs showed a strong signal for let-7a miRNA and served as a positive control. However, the scrambled-miRNA sequence did not show any effects. These results indicate that activation of MMCs with EphrinA1 induces the expression of let-7 miRNA when compared with untreated control MMCs. (Figure 2a) . MMCs' total lysates were subjected to western blot analysis and b-actin levels were measured to demonstrate equal sample loading. In situ hybridization to demonstrate the expression of let-7a miRNA in MMC1. Left panels were probed with digoxigenin (DIG)-labeled hsa-let-7a miRCURYt locked nucleic acid (LNA) probe; right panels were probed with scrambled sequences. In EphrinA1-activated cells, a punctate staining was predominant in the cytoplasmic region and it was absent when the cells were probed with scrambled sequences (middle panels). In control cells (upper panels), the let-7a miRNA expression was undetected. MMC1 transfected with let-7a precursor used as positive control demonstrated strong signal for let-7a in MMC1 (lower panels). Nuclear fast red was used for counter-staining. Arrows points to let-7a-positive staining. All images were acquired at Â 200 magnification using Nikon microscope. (Figures 2b and c) . RAS signaling plays an important role in the pathogenesis of MMCs. We determined if RAS protein expression was modulated in EphrinA1-activated MMCs. We noticed that the activation of EphA2, with its ligand EphrinA1, downregulated the expression of RAS protein in a timedependent manner in MMCs (Figure 2d ). Stimulation with EphrinA1 at a concentration of 3 mg for 24 h significantly decreased RAS protein levels when compared to 6 h of activation. The untreated MMCs showed strong expressions of RAS in both MMC1 and MMC2. The RAS expression was significantly downregulated at 24 h, indicating that receptor EphA2 activation initiates the oncogene-suppressive signaling. In (a, c and d) , the upper plate shows relative densities of EphA2, the middle plate shows EphA2 expression and the lower plate b-actin expression. The b-actin was detected to demonstrate equal sample loading. Data presented was ± s.e.m. of three separate experiments. *Po0.001, EphrinA1-activated versus control MMCs.
EphrinA1 downregulates
EphA2 and RAS oncogene expression in MMCs Receptor EphA2 was overexpressed in both MMC1 and MMC2 cell lines
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MiRNA let-7 downregulates RAS expression in MMCs
To confirm that EphrinA1 regulates the expression of the RAS genes through let-7 miRNA expression and to determine the role of let-7 in RAS oncogene repression in MMCs, MMCs were transfected either with let-7a miRNA antisense 2 0 -OMO (50 nM) or mis-MO. The cells were subsequently activated with EphrinA1, and RAS protein levels were monitored 24 h post-activation by immunoblotting and immunofluorescence microscopy (Figures 3a and b) . Untreated MMCs showed strong cytoplasmic signal for RAS, whereas in EphrinA1-activated MMCs, RAS expression was downregulated. When MMCs were transfected with let-7 2 0 -OMO and activated with EphrinA1, the expression of RAS was restored and was comparable to unstimulated cells (Figures 3a and b) . In addition, when MMCs were transfected with mis-MO and activated with EphrinA1, the RAS expression was significantly decreased. Let-7a precursor significantly downregulated the expression of RAS when compared to scrambled control (Figure 3a) . (Figure 3c) . In EphrinA1-activated MMCs, the expression of K-RAS and N-RAS was relatively less depressed, indicating that the transfection of MMCs with let-7 antisense oligos attenuated the expression of H-RAS. These data suggest that EphrinA1 inhibits RAS expression via induction of let7a1, let-7a3, let-7f1 and let-7f2 miRNAs in MMCS, a novel mechanism.
The mechanism for the let-7 miRNA-mediated decreases in RAS oncogenes mRNA was also investigated by transient transfection of let-7a miRNA precursor (Figures 4a-c) . MMCs were transfected with let-7a precursor and harvested at 36 h post-transfection for the Scanning of the immunoblots indicated about 65 and 88% decrease of the RAS expression upon transfection with 50 and 100 nM of let-7a pre-miRNA, respectively, in MMCs (Figure 4a ). In addition, this decrease in RAS was also confirmed by in situ immunofluorescence staining. The expression of RAS was significantly decreased in let7a pre-miRNA-transfected MMCs when compared to scrambled-miRNA (Figure 4b) . Furthermore, MMCs were transfected with let-7a pre-miRNA and the expression of RAS was also determined by qPCR (Figure 4c) . The transient expression of let-7a miRNA in MMCs significantly inhibited the expression of all the three isoforms, particularly H-RAS, when compared to scrambled-miRNA. However, the magnitude of K-RAS and N-RAS inhibition was low compared to H-RAS. Our data support that let-7 directly regulates all three RAS genes, the important cell cycle proto-oncogenes in MMCs. Taken together, these data suggest that let-7a miRNA controls the expression of oncogene RAS in MMCs.
EphrinA1-induced miRNA let-7 miRNA attenuates MMC proliferation To determine whether EphrinA1-induced let-7 miRNA plays a role in the regulation of MMC proliferation, we examined cell proliferation by WST-1 expression and direct cell counts after transfection with the let-7 inhibitor (antisense 2 0 -OMO) and by transfecting with the let-7 precursor, respectively. Parallel controls were maintained by including scrambled sequences. The cell cultures were treated with or without 2 0 -OMO for 2 h in triplicate cultures and then stimulated with EphrinA1 for 24 h. The proliferation rate was significantly reduced in EphrinA1-activated MMCs when compared to untreated control MMCs (Figures 5a-d) . In contrast, when the cells were pretreated with 2 0 -OMO (which inhibits let-7 activity), EphrinA1 activation did not affect the proliferative response, which was comparable to untreated control cells. In addition, let-7a precursor-transfected MMCs demonstrated the lowest proliferation with or without EphrinA1 activation. The scrambled-miRNA sequence did not show any effect. These data suggest that the proliferation is regulated through the let-7a miRNA expression in MMCs.
EphrinA1 treatment inhibits tumor growth via let-7 miRNA expression in three-dimensional Matrigels MMCs were transfected with let-7 miRNA antisense 2 0 -OMO or mis-MO before being activated with EphrinA1 and were seeded onto Matrigels to determine the clonal expansion and tumor growth in vitro. The tumor growth was monitored for about 2 weeks. Light microscopic examination revealed that MMCs stimulated with EphrinA1 suppressed tumor growth on three-dimensional Matrigel when compared to control cultures (Figure 6a) . In contrast, when the cells were transfected with 2 0 -OMO (which inhibits let-7 activity), the EphrinA1 activation failed to affect the tumor growth and the response was comparable to untreated proliferating cells (Figure 6a , middle panels). The mis-MO did not show any effect and was comparable to control MMCs. In MMC1 transfected with let-7a precursor, tumor growth was significantly attenuated and the scrambled sequences had no effect (Figure 6b ). Similar obervations were noticed in MMC2 (data not presented).
Discussion
MM continues to be a frustrating clinical problem with no definitively effective therapy. Various therapeutic approaches including surgery, radiotherapy, chemotherapy and even gene therapy have been trialed to improve survival rates in patients, all showing limited to no success. 29 Survival pathways are almost altered in tumors, and most studies to date support the notion that Ephrinmediated signals are tumor suppressive. 10, [30] [31] [32] Previously, we have shown that EphA2 receptor activation by its ligand EphrinA1 suppresses proliferation and tumor growth in MM. 12 In this report, we demonstrated that Malignant mesothelioma and let-7 microRNA N Khodayari et al EphA2 receptor activation by recombinant EphrinA1 leads to a significant overexpression of let-7a miRNA and results in a downregulation of RAS proto-oncogene in MMCs. Transfection of MMCs with let-7 miRNA antisense oligos (2 0 -OMO), before ligand activation, significantly restored the RAS expression and enhanced proliferation. Furthermore, in MMCs the let-7a miRNA overexpression resulted in a significant suppression of RAS oncogene and an inhibition of MMC proliferation and tumor growth in vitro.
Several RTK pathways including epidermal growth factor receptor, insulin-like growth factor receptor and hepatocyte growth factor are known to be activated in MM. 15, 33, 34 Each of these RTKs are known to signal through RAS, suggesting that RAS signaling pathway plays an important role in MM growth. Recent characterization of let-7 regulation of RAS proto-oncogene indicates that this molecular pair plays a critical role in the control of proliferation in many different tumor cells. [35] [36] [37] MiRNAs regulate the gene expression posttranscriptionally by binding to the 3 0 -untranslated region of target mRNAs. In addition, miRNA binding leads to the degradation of target mRNA and subsequently reduced the translation of the target protein. MiRNA activity also affects the expression of genes that are downstream of direct targets and results in the modulation of global protein profiles. In this study, an inverse association between RAS oncoprotein level and let-7a expression was observed in EphrinA1-activated MMCs. In normal cells, let-7 is expressed at higher levels than tumor cells, 38 and it directly controls cellular proliferation by negatively regulating the RAS genes. 39 In some malignancies, most or all let-7 family cluster appears to be downregulated, 40 for example, low expression of let-7e was found in MMs. 41 In melanoma the let-7b and in colon cancer the let-7a expressions were reported to be greatly reduced. 42, 43 The direct regulation of RAS by let-7 was confirmed in non-small-cell lung cancer, where Kumar et al., 44 demonstrated that let-7g controlled tumor growth via suppression of RAS in a mouse model. The let-7s is required for terminal differentiation during embryonic development. In addition, let-7s regulates high-mobility group AT-hook2 expression in squamous cell carcinoma. 45 We noticed increased expression of let7a1, let-7a3, let7f1 and let-7f2 in EphrinA1-activated MMCs. Interestingly, let-7a1 expression was fivefold higher than that compared to other let-7 isoforms, indicating that EphrinA1 signaling predominantly induces let-7a in MMCs. Our data also demonstrated that let-7a transfection attenuated the mRNA expression of all three RAS genes, the important cell cycle proto-oncogenes in MMCs. However, the H-RAS inhibition was more prominent than that compared to K-RAS and N-RAS. In addition, transfection with antisense 2 0 -OMO to let-7 miRNA, before activation with EphrinA1, resulted in complete de-repression of H-RAS, whereas the K-RAS and N-RAS isoforms were partially de-repressed in MMCs. This suggests that the let-7a expression in EphrinA1-activated MMCs targets the H-RAS oncogene and thereby inhibits the downstream signals mediated through EphA2, thus stalling the oncogenic process in MMs. Our observation that silencing let-7a with antisense 2 0 -OMO indicates that, in MM, the EphrinA1 signaling-mediated inhibition of tumor growth was mediated through let-7a induction. This was further supported by our data that transient expression of let-7a by transfection in MMCs completely attenuated the MM tumor growth.
Recent reports on miRNA profiling of cancerous tissues revealed that miRNA let-7 is downregulated in lung cancer when compared with the adjacent normal lung tissues. 40, 46 In addition, reduced expression of let-7a was directly correlated with the poor survival of patients with lung adenocarcinoma. 38 Although our knowledge towards understanding the functions of miRNA is still emerging, it is evident from the current investigation that EphrinA1 engagement with receptor EphA2 significantly upregulated the expression of let-7a miRNA in MMCs. The attenuation of tumor colony formation further necessitates the extended function of EphrinA1 beyond cytoskeletal reorganization and downregulation of RAS oncogene. Thus, EphrinA1 binding to receptor EphA2 can effectively upregulate the expression of let-7a and could be a potential strategy to reduce tumor burden. However, the association of EphrinA1 and let-7a miRNA signaling network warrants further studies in MMCs.
In conclusion, our findings identified a novel mechanism of EphrinA1-mediated tumor-suppressive signaling in MMCs. This is the first report which revealed that the tumor-suppressive properties of EphrinA1 are due to the expression of let-7a miRNA, which target RAS oncogene in MMCs. These data account for one of the mechanisms underlying the antiproliferative functions of EphrinA1, as evidenced by decreased tumor growth in MMs. However, further work needs to be performed to learn more about the EphrinA1-mediated antitumorogenesis mechanisms in MMCs.
